Status of intraductal therapy for ductal carcinoma in Situ

Current Breast Cancer Reports

Volumn 2, Issue 2, 2010, Pages 75-82

  Flanagan, Meghan ^a   Love, Susan ^b   Hwang, E Shelley ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Carcinoma in situ (DCIS); Ductal lavage; Intraductal therapy; Preinvasive cancer

Indexed keywords

4 HYDROXYTAMOXIFEN; CARBOPLATIN; DOXORUBICIN; TAMOXIFEN; TUMOR MARKER;

ABLATION THERAPY; BREAST CANCER; BREAST EPITHELIUM; BREAST TENDERNESS; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CYTOLOGY; DIAGNOSTIC PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG DOSE ESCALATION; DUCTOSCOPY; ENDOSCOPY; ERYTHEMA; EXCISION; HUMAN; INTRADUCTAL CARCINOMA; INTRADUCTAL DRUG ADMINISTRATION; INTRADUCTAL THERAPY; LAVAGE; MASTITIS; NIPPLE ASPIRATION; NONHUMAN; PARTIAL MASTECTOMY; PATIENT MONITORING; PILOT STUDY; REVIEW; SIDE EFFECT;

EID: 77953132622     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-010-0015-3     Document Type: Review

References (47)

1. Virnig BA, Shamliyan T, Tuttle TM, et al.: Diagnosis and Management of Ductal Carcinoma In Situ (DCIS): Evidence Report/Technology Assessment. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; 2009:171
2. Lewis JP: The Breast Cancer Continuum: insights from the tamoxifen trials impact future drug development strategies. Ann N Y Acad Sci 2001, 949:327-332.
3. Sanders ME, Schuyler PA, Dupont WD, et al.: The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term followup. Cancer 2005, 103:2481-2484.
4. Page DL, Dupont WD, Rogers LW, et al.: Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982, 49:751-758.
5. Betsill WL Jr, Rosen PP, Lieberman PH, et al.: Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 1978, 239:1863-1867.
6. Eusebi V, Feudale E, Foschini MP, et al.: Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994, 11:223-235.
7. Smith GL, Smith BD, Haffty BG: Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int JRadiat Oncol Biol Phys 2006, 65:1397-1403.
8. Silverstein MJ, Cohlan BF,Gierson ED, et al.:Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 1992, 28:630-634.
9. Rakovitch E, Franssen E, Kim J, et al.: A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003, 77:285-293.
10. Partridge A: Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from acohort study. J Natl Cancer Inst 2007, 100:243-251
11. Cooper A: On the Anatomy of the Breast. London: Longman, Orme, Green, Brown and Longmans; 1840
12. Hovey RC, Trott JF, Vonderhaar BK: Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia 2002, 7:17-38.
13. Teboul M: A new concept in breast investigation: echohistological acino-ductal analysis or analytic echography. Biomed Phamacother 1988, 42:289-295.
14. Moffat DF, Going JJ: Three dimensional anatomy of complete duct systems in human breast: pathological and developmental implications. J Clin Pathol 1996, 49:48-52.
15. Love SM, Barsky SH: Anatomy of the nipple and breast ducts revisited. Cancer 2004, 101:1947-1957.
16. Cooper A: The Anatomy and Diseases of the Breast. Philadelphia: Lea and Blanchard; 1845.
17. Dietz JR, Crowe JP, Grundfest S, et al.: Directed duct excision by using mammary ductoscopy in patients with pathologic nipple discharge. Surgery 2002, 132:582-587; discussion 587-588.
18. Dooley WC, Ljung BM, Veronesi U, et al.: Ductal lavage for detection of cellular atypic in women at high risk for breast cancer. J Natl Cancer Inst 2001, 93:1624-1632.
19. Page DL, Dupont WD, Rogers LW, Rados MS: Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985, 55:2698-2708.
20. Wrensch M, Petrakis NL, King EB, et al.: Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol 1993, 137:829-833.
21. Wrensch MR, Petrakis NL, Miike R, et al.: Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001, 93:1791-1798.
22. Fabian CJ, Kimler BF, Zalles CM, et al.: Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000, 92:1217-1227.
23. Khan SA, Wiley EL, Rodriguez N, et al.: Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst 2004, 96:1510-1517.
24. Maddux AJ, Ashfaq R, Naftalis E, et al.: Patient and duct selection for nipple duct lavage. Am J Surg 2004, 188:390-394.
25. Brogi E, Robson M, Panageas KS, et al.: Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. Cancer 2003, 98:2170-2176.
26. Wood ME, Stanley MA, Crocker AM, et al.: Ductal lavage of cancerous and unaffected breasts: procedure success rate and cancer detection. Acta Cytol 2009, 53:410-415.
27. Sartorius OW, Smith HS, Morris P, et al.: Cytologic evaluation of breast fluid in the detection of breast disease. J Natl Cancer Inst 1977, 59:1073-1080.
28. Chatterton RT Jr, Geiger AS, Khan SA, et al.: Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13:928-935.
29. Khan SA, Wolfman JA, Segal L, et al.: Ductal lavage findings in women with mammographic microcalcifications undergoing biopsy. Ann Surg Oncol 2005, 12:689-696.
30. King BL, Tsai SC, Gryga ME, et al.: Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Clin Cancer Res 2003, 9:1509-1516.
31. Krishnamurthy S, Zhao L, Hayes K, et al.: Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. Cancer 2004, 102:322-327.
32. Adduci KM, Annis CE, DeVries S, et al.: Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer. Cancer 2007, 111:185-191.
33. Zhang W, Yang YC, Zhang BN, et al.: Biomarker analysis on breast ductal lavage cells in women with and without breast cancer. Int J Cancer 2006, 119:359-364.
34. Krassenstein R, Sauter E, Dulaimi E, et al.: Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004, 10:28-32. (Pubitemid 38114158)
35. Fackler MJ, Malone K, Zhang Z, et al.: Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006, 12:3306-3310.
36. Sauter ER, Shan S, Hewett JE, et al.: Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005, 114:791-796.
37. Uchida K, Fukushima H, Toriumi Y, et al.: Mammary ductoscopy: current issues and perspectives. Breast Cancer 2009, 16:93-96.
38. ·· Kapenhas-Valdes E, Feldman SM, Cohen JM, et al.: Mammary ductoscopy for evaluation of nipple discharge. Ann Surg Oncol 2008, 15:2720-2727. The authors present a single-institution study of 110 ducts in 93 patients evaluated with ductoscopy, including patient presentation, ductoscopic/pathologic findings, and surgical outcome. The potential for future diagnostic and therapeutic applications of this procedure is discussed.
39. ·· Dooley WC: Ductoscopy technique-using ductoscopy anatomically direct breast conservation surgery. From 6th International Symposium on the Intraductal Approach to Breast Cancer. Santa Monica, CA. BMC Proceedings 2009, 3(Suppl 5):S16. This collection of monographs represents the current state of the art in intraductal therapy and includes brief summaries of recent and ongoing studies of intraductal therapy for both benign and malignant breast disease. Both practical and theoretical considerations for intraductal therapy are reviewed.
40. Murata S, Kominsky SL, Vali M, et al.: Ductal access for prevention and therapy of mammary tumors. Cancer Res 2006, 66:638-645.
41. Stearns V, Jacobs L, Khouri N, et al.: A phase I study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women awaiting mastectomy. From 6th International Symposium on the Intraductal Approach to Breast Cancer. Santa Monica, CA. BMC Proceedings 2009, 3(Suppl 5):S28
42. Rao JY, Yang H, Zhang BN, et al.: Histopathological responses to a short term intraductal cytotoxic agent treatment: results of a feasibility study, 6th International Symposium on the Intraductal Approach to Breast Cancer. Santa Monica, CA. BMC Proceedings 2009, 3(Suppl 5):S30.
43. Love S, Zhang BN, Zhang W, et al.: Local drug delivery to the breast: a phase I study of breast cytotoxic agent administration prior to mastectomy, 6th International Symposium on the Intraductal Approach to Breast Cancer. Santa Monica, CA. BMC Proceedings, 2009, 3(Suppl 5):S29
44. ·· Mahoney M, Mills D, Love S: Intraductal therapy of DCIS with liposomal doxorubicin: a preoperative trial in rural California, 6th International Symposium on the Intraductal Approach to Breast Cancer. Santa Monica, CA.BMC Proceedings 2009, 3(Suppl 5):S31. This collection of monographs represents the current state of the art in intraductal therapy and includes brief summaries of recent and ongoing studies of intraductal therapy for both benign and malignant breast disease. Both practical and theoretical considerations for intraductal therapy are reviewed.
45. Bhandare D, Nayar R, Bryk M, et al.: Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:2620-2627.
46. ·· Patil DB, Lankes HA, Nayar R, et al.: Reproducibility of ductal lavage cytology and cellularity over a 6 month interval in high risk women. Breast Cancer Res Treat 2008, 112:327-333. This interesting study explores whether ductal lavage may be used to serially follow patients at high risk for breast cancer. This may be of potential relevance in the future if both therapy and followup of treatment are to be managed through an intraductal approach.
47. Khan SA, Lankes HA, Patil DB, et al.: Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res 2009, 2:265-273.